Swiss pharmaceutical giant Roche said the US Food and Drug Administration gave its green light to its FoundationOne CDx personalized diagnostic cancer test
The US Food and Drug Administration gave Roche the green light for its test FoundationOne CDx personalized cancer diagnosis, Swiss Group said Monday.
Roche said the FDA had approved the test by helping doctors understand the genetic profile of patients' tumors to allow for better targeted therapies and clinical trials.
"The approval of FoundationOne CDx represents a breakthrough in the personalization of cancer treatment, facilitating access for patients in the US to a complete complementary pan-tumor diagnosis that will help identify treatment options approved based on the molecular footprint of each individual's cancer, "said Roche medical director Sandra Horning, also director of global product development at the firm.
"We believe that profiling will become routine in clinical practice, so we have worked closely with Foundation Medicine to develop a clinically and badytically validated platform that can support existing and future diagnostic needs," Horning said. a declaration.
Pharmaceutical companies see the development of a personal treatment measure as the way forward to address cancer.